Business
Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M QoQ
Stable revenue and gross profit despite cost-cutting initiatives, indicating the strength of underlying segments and brands.Solid liquidity position, with
About this update from Cosmos Health Inc.
[{"type":"text","content":"Stable revenue and gross profit despite cost-cutting initiatives, indicating the strength of underlying segments and brands.Solid liquidity position, with cash and cash equivalents exceeding $3.3 million.Hard assets, mainly comprised of debt-free properties, valued at over $12 million; exceeding total debt and providing financing flexibility.Liquid inventory position and accounts receivable that are collected at an accelerated pace provide additional flexibility.Record-breaking results at CosmoFarm and in Amazon UK sales.Various cost-cutting and efficiency initiatives are underway as revenue accelerates, with a focus on high-margin segments like CMO and proprietary brands.CHICAGO, IL / ACCESSWIRE / November 15, 2024 / Cosmos Health Inc. (\"Cosmos Health\" or the \"Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the third quarter ended September 30, 2024.Third Quarter 2024 Financial HighlightsIncome Statement:Revenue decreased by 3.22%, or $0.41 million, to $12.41 million, down from $12.82 million in Q3 2023.For the nine months ended September 30, 2024, revenue rose by 7.1%, or $2.67 million, reaching $40.20 million compared to $37.5 million for the same period last year.Gross profit held steady at $1.21 million versus Q3 2023.For the nine-month period ending September 30, 2024, gross profit increased by 6.1%, or $0.19 million, totaling $3.31 million, up from $3.12 million year-over-year.Gross margin increased to 9.72%, up 25 basis points from 9.47% in Q3 2023.Operating Expenses were reduced by 18.6%, or $0.79 million, to $3.45 million from $4.23 million in Q3 2023, driven by a 30.7% decline in general and administrative costs and a 73.42% drop in sales and marketing expenses.For the nine months ending September 30, 2024, operating expenses declined by 13%, or $1.48 million, to $9.89 million from $11.36 million for the comparable period last year.Loss from operations improved, decreasing by 25.77%, or $0.78 million, to $2.24 million, down from $3.02 million in Q3 2023.For the nine-month period ending September 30, 2024, operational losses dropped by 20.22%, or $1.67 million, to...